Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001558370-20-003993
Filing Date
2020-04-17
Accepted
2020-04-17 13:50:25
Documents
12
Period of Report
2020-06-17

Document Format Files

Seq Description Document Type Size
1 PRE 14A imgn-20200617xpre14a.htm PRE 14A 1641822
2 GRAPHIC imgn-20200617xpre14ag001.jpg GRAPHIC 6743
3 GRAPHIC imgn-20200617xpre14ag002.jpg GRAPHIC 9391
4 GRAPHIC imgn-20200617xpre14ag003.jpg GRAPHIC 4594
5 GRAPHIC imgn-20200617xpre14ag004.jpg GRAPHIC 5130
6 GRAPHIC imgn-20200617xpre14ag005.jpg GRAPHIC 1762
7 GRAPHIC imgn-20200617xpre14ag006.jpg GRAPHIC 27102
8 GRAPHIC imgn-20200617xpre14ag007.jpg GRAPHIC 27876
9 GRAPHIC imgn-20200617xpre14ag008.jpg GRAPHIC 62161
10 GRAPHIC imgn-20200617xpre14ag009.jpg GRAPHIC 15200
11 GRAPHIC imgn-20200617xpre14ag010.jpg GRAPHIC 80097
12 GRAPHIC imgn-20200617xpre14ag011.jpg GRAPHIC 57239
  Complete submission text file 0001558370-20-003993.txt   2054007
Mailing Address 830 WINTER ST WALTHAM MA 02451
Business Address 830 WINTER ST WALTHAM MA 02451 (781)895-0600
ImmunoGen, Inc. (Filer) CIK: 0000855654 (see all company filings)

EIN.: 042726691 | State of Incorp.: MA | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-17999 | Film No.: 20798845
SIC: 2834 Pharmaceutical Preparations